Skip to main content
. 2019 Aug 23;79(14):1683–1691. doi: 10.1002/pros.23893

Figure 2.

Figure 2

CONSORT diagram. aTypes of clinical progression leading to discontinuation were prostate‐specific antigen progression (n = 5) and Eastern Cooperative Oncology Group (ECOG) performance status change (n = 1). The reason for discontinuation due to patient request was inability to travel to the clinic (n = 2). AE, adverse event [Color figure can be viewed at wileyonlinelibrary.com]